Nanexa AB (publ) (STO:NANEXA)
Sweden · Delayed Price · Currency is SEK 3.610
+0.035 (0.98%)
May 6, 2026, 5:24 PM CET
Nanexa AB Revenue
Nanexa AB had revenue of 6.15M SEK in the quarter ending March 31, 2026, a decrease of -19.59%. This brings the company's revenue in the last twelve months to 54.32M, up 34.38% year-over-year. In the year 2025, Nanexa AB had annual revenue of 55.94M with 19.80% growth.
Revenue (ttm)
54.32M
Revenue Growth
+34.38%
P/S Ratio
10.83
Revenue / Employee
3.62M
Employees
15
Market Cap
588.39M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 55.94M | 9.24M | 19.80% |
| Dec 31, 2024 | 46.69M | -12.47M | -21.07% |
| Dec 31, 2023 | 59.16M | 31.99M | 117.72% |
| Dec 31, 2022 | 27.17M | 9.16M | 50.87% |
| Dec 31, 2021 | 18.01M | -2.85M | -13.66% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioGaia AB | 1.54B |
| EQL Pharma AB | 425.75M |
| Cinclus Pharma Holding AB | 57.47M |
| Enzymatica AB | 53.06M |
| Cereno Scientific AB | 44.27M |
| Newbury Pharmaceuticals AB | 32.78M |
| Orexo AB | 17.80M |
| Moberg Pharma AB | 13.54M |
Nanexa AB News
- 2 years ago - Nanexa AB Earnings Call Transcript: Q1 2024 - Transcripts
- 5 years ago - Nanexa AB Transcript: Business Update - Transcripts